



EMBS Micro and Nanotechnology in Medicine Conference

TRANSLATING TECHNOLOGY FROM THE BENCH TO THE BEDSIDE

12-16 December 2016

Waikoloa, Hawaii

Commercialization Panel: “Investing to Create the Future of Medicine”

Tuesday, December 13, 2016

8-10pm

PANELIST BIOGRAPHIES

Hemai Parthasarathy, Ph.D.

Hemai Parthasarathy is the Scientific Director of Breakout Labs and the Thiel Foundation. She is responsible for establishing the scientific priorities of the program and evaluating the technical merits of submitted proposals. Hemai brings a deep commitment to scientific innovation and communication to Breakout Labs. She has served as the North American Editor for Nature and was a founding editor of PLOS, the open-access publisher of PLOS ONE. Before joining the Thiel Foundation, she advised research institutes, non-profits, and biotechnology companies on the development and communication of their scientific portfolios. She holds a Ph.D. in Brain and Cognitive Sciences from the Massachusetts Institute of Technology.

Elias Caro

Elias is VP of Technology Development in charge of the grant programs in biomedical research at the Wallace H. Coulter Foundation where he joined in 2006. From 1998 to 2006 in Beckman Coulter, he occupied positions of increasing responsibility as Vice President of Diagnostic R&D, President of the Biomedical Research Division and Executive Vice President in charge of International Diagnostics Commercial Operations and Worldwide Life Sciences. From 1985 to 1998 for Coulter Corporation, he managed several international operations in Latin America, France, Belgium and Japan. Elias holds a Bachelor degree in Industrial Engineering, Masters in Business and Polymer Science and is an AIMBE fellow.

D.A. Wallach

D.A. Wallach is best known as a recording artist and songwriter who Kanye West and Pharrell Williams discovered while he was an undergraduate at Harvard College. He has been featured in GQ, Rolling Stone, Vogue, and numerous other publications, and has performed on TV Shows including Jimmy Kimmel Live and Late Night with Jimmy Fallon. His solo debut for Capitol Records, *Time Machine*, is available at www.TimeMachineAlbum.com. As an investor, D.A. has backed groundbreaking technology businesses, including Spotify, Doctor On Demand, SpaceX, Ripple, and DAQRI. Forbes selected D.A. as one of its 30 Under 30 and Fast Company named him one of the 100 Most Creative People in Business.

Eric Moessinger

Eric joined NanoDimension in 2008 and was the first employee of NanoDimension’s Silicon Valley office. He is involved in deal sourcing, due diligence and deal structuring and focuses on NanoDimension’s life sciences investments together with Carl Pabo and Colin Walsh. He is a board member of Emulate, Pulse Therapeutics, Muse Biotechnology, SQZ Biotech and a board observer of Twist Bioscience, IonPath and Click Diagnostics. Previously, Eric was a consultant at Bain & Company in Zurich and San Francisco. While at Bain, Eric worked on strategy cases in healthcare, industrial goods and telecommunications and on the turn-around of an electrical component manufacturer. In addition, Eric spent eight months in Bain’s Private Equity Group. Eric has an MS.c. from the London School of Economics and a BS/BA from the University of

Florida.

Kelly LaMarco, Ph.D.

Since its launch in 2009, Kelly LaMarco has been Senior Editor at *Science Translational Medicine*, where she oversees the Commentary section of the journal. After receiving her M.S. and Ph.D. in Biochemistry, Dr. Kelly LaMarco performed her postdoctoral research on mammalian transcriptional regulation at the Carnegie Institution of Washington. She then served as an Associate Editor for the journal *Science*, where she performed manuscript selection and editing. Dr. LaMarco next worked as a Staff Scientist and Project Leader of the Infectious Diseases Drug Discovery program at Tularik Inc., a then–privately held biotechnology company. After leaving Tularik, she obtained funding for, led the development of, and served as Editorial Director of the *Science of Aging Knowledge Environment* (SAGE KE), AAAS's Web-based journal for researchers in the field of aging. At the same time she served as an editor for the policy Web site SAGE Crossroads, which was co-developed by the Alliance for Aging Research and AAAS. Dr. LaMarco also was the Director of West Coast Alliances for the New York Academy of Sciences and, in her spare time, worked as a scientific writer, editor, and consultant in academics and in the private sector.

Jesus Soriano, M.D., Ph.D.

Jesus Soriano joined the NSF in February 2012 as a Program Director in Biological and Chemical Technologies, after 20 years of international experience in executive leadership in the biopharmaceutical and non-profit sectors, start-up formation and funding, technology commercialization, and academic teaching and research. Prior to NSF, he was the Senior Advisor to the Puerto Rico Trust for Science, Technology and Research, a technology-based development organization. Previously, he was Executive Vice President at QRxPharma, Ltd., a clinical-stage specialty pharmaceutical company focused in pain management and central nervous system disorders. Before, he was Senior Director of Business Development at Osiris Therapeutics, Inc. Previously, he held several executive leadership positions at the global bioresource center ATCC, including Vice President for IP, Licensing and International Business Development, and was Associate Director for R&D Operations and Business Development at Entremed, Inc, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer. Jesus began his career as a family doctor in Spain; he then worked at the University of Geneva Medical School, Switzerland initially as Research Scientist and then as Assistant Professor. He initially came to the US as a visiting scientist to the National Cancer Institute (NIH) under an advanced researcher fellowship from the Swiss National Science Foundation. He holds a MBA in Corporate Finance from the Johns Hopkins Carey Business School; a Ph.D. in Medical Sciences from the University of Geneva, Switzerland; and a M.D. from the University of Alicante, Spain.

Dean Ho, Ph.D. (Moderator)

Dr. Dean Ho is currently Professor of Bioengineering, and Oral Biology and Medicine at UCLA, and Co-Director of the Weintraub Center for Reconstructive Biotechnology. He is also currently the director of Project NDX, a global initiative to develop and clinically translate novel nanodiamond-based cancer therapies. He recently initiated a clinical trial to validate a nanodiamond-embedded biomaterial to enhance root canal surgery outcomes (NCT02698163). Dean has served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 26,000-member global drug development organization comprised of senior executives from the pharmaceutical and medical device sectors. Under the leadership of the Executive Team and Board of Directors, SLAS experienced substantial global expansion activity through mergers and acquisitions as well as strategic partnerships that established international offices, bringing the organization into China (Shanghai) and Europe (Brussels). He is a co-founder of Biotic Labs (Exit via O-Ray Pharma), and RAEN Biotech. He also currently serves on the advisory board of Q Venture Partners and Bikanta (Y-Combinator). Dean is an AIMBE Fellow and has been featured in *The Economist*, *Washington Post*, *National Geographic Channel*, *NPR* and other international news outlets. Dean Ho is also Co-Founder and Chairman of KYAN Therapeutics, a revenue-stage biotechnology company. KYAN's CURE8™ technology portfolio has realized best-in-class, clinically validated combination therapies for indications ranging from cancer to infectious diseases and metabolic disorders.